1. Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
- Author
-
Castoldi, G, Carletti, R, Barzaghi, F, Meani, M, Zatti, G, Perseghin, G, Di Gioia, C, Zerbini, G, Castoldi G., Carletti R., Barzaghi F., Meani M., Zatti G., Perseghin G., Di Gioia C. R. T., Zerbini G., Castoldi, G, Carletti, R, Barzaghi, F, Meani, M, Zatti, G, Perseghin, G, Di Gioia, C, Zerbini, G, Castoldi G., Carletti R., Barzaghi F., Meani M., Zatti G., Perseghin G., Di Gioia C. R. T., and Zerbini G.
- Abstract
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering agents widely used for the treatment of type 2 diabetes mellitus. A number of clinical trials in type 2 diabetic patients with different degrees of renal impairment have clearly demonstrated that SGLT2 inhibitors reduce the progression rate of diabetic kidney disease. Furthermore, recent studies have shown that SGLT2 inhibitors also exert a protective effect in the case of non-diabetic kidney disease. Consequently, it has been hypothesized that the nephroprotective activity of these drugs could exceed the canonical impact on glycemic control and that the resulting beneficial effects could be the consequence of their pleiotropic properties (proven reduction of inflammation, fibrosis, oxidative stress and sympathetic nervous activity) both at systemic and tissue levels, suggesting that the efficacy of these drugs could also be extended to non-diabetic nephropathies. This review focuses on the nephroprotective effects of SGLT2 inhibitors in different experimental models of non-diabetic kidney disease. The different glucose-independent mechanisms potentially implemented by SGLT2 inhibitors to ultimately protect the non-diabetic kidney are described in detail, and conflicting results, when present, are discussed.
- Published
- 2024